NodThera is advancing new insights into innate immunity to create a robust product engine to identify pipeline molecules with the greatest therapeutic impact. A rapidly growing body of research shows that selectively inhibiting the activation of the Nod-like receptor protein NLRP3 inflammasome can significantly attenuate inflammatory processes without broadly suppressing the immune system. NLRP3 has emerged as one of the most promising therapeutic targets in immunobiology today.
Building on their knowledge of the medicinal chemistry, biological activity and mechanism of action of NLRP3 inflammasome inhibitors, they are creating a next-generation pipeline of small molecules that are optimized for potency, PK and tissue penetration. They are also optimizing for structural attributes that enable individual candidate molecules to be targeted to specific disease indications.